Day

June 29, 2020

29
Jun
2020

Q&A with Regeneron SVP David Weinreich on Therapeutic Neutralizing Antibodies

Public discussion about the role of biotech and pharma in the pandemic tends to focus on one of two areas. Vaccines are the great hope, and occupy center stage. Gilead’s remdesivir has captured considerable attention, largely by being the first approved drug for COVID-19, despite offering a limited benefit for hospitalized patients. Off in the periphery of the public mind...
Read More